BIO-Europe Spring: Pharma Dealmaking in Lisbon
CNS may finally be emerging from its long discussed graveyard. Oncology dealmaking is becoming more selective. And sourcing innovation from China is no longer something to be coy about. These were some of my takeaways from BIO-Europe Spring in Lisbon last week, where the Evaluate team was on the ground sharing data led insight on […]
